Current Drug Research Reviews最新文献

{"title":"Cutting-edge nanotechnological approaches for lung cancer therapy.","authors":"Amaiyya Agrawal, Sankha Bhattacharya","doi":"10.2174/2589977514666220418085658","DOIUrl":"https://doi.org/10.2174/2589977514666220418085658","url":null,"abstract":"Lung cancer is the second leading cancer with a high rate of mortality. It can be treated using different intervention techniques such as chemotherapy, radiation therapy, surgical removal, photodynamic therapy. All of these interventions lack specificity, which implies that it harms the normal cells adjacent to the infected ones. Nanotechnology provides a promising solution that increases the bioavailability of anticancer drugs at the tumor site with reduced toxicity and improved therapeutic efficacy. Nanotechnology also improved the way lung cancer is diagnosed and treated. Various types of nanocarriers like liposomes, polymeric nanoparticles, magnetic nanoparticles, and different theranostic approaches are already approved for medical use, while various are under clinical and preclinical stages. This review article covers the details pertaining to lung cancer, types of overexpressed receptors, and cutting-edge nanocarriers used for treating lung cancer at its specific target.","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42929222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are histamine H3 antagonists the definitive treatment for acute methamphetamine intoxication?","authors":"N. Kitanaka, F. Hall, Koh-ich Tanaka, K. Tomita, Kento Igarashi, Nobuyoshi Nishiyama, Tomoaki Sato, G. Uhl, J. Kitanaka","doi":"10.2174/2589977514666220414122847","DOIUrl":"https://doi.org/10.2174/2589977514666220414122847","url":null,"abstract":"BACKGROUND\u0000Methamphetamine (METH) is classified as a Schedule II stimulant drug under the United Nations Convention on Psychotropic Substances of 1971. METH and other amphetamine analogues (AMPHs) are powerful addictive drugs. Treatments are needed to treat the symptoms of METH addiction, chronic METH use, and acute METH overdose. No effective treatment for METH abuse has been established because alterations of brain functions under excessive intake of abused drug intake are largely irreversible due in part to brain damage that occurs in the course of chronic METH use.\u0000\u0000\u0000OBJECTIVE\u0000Modulation of brain histamine neurotransmission is involved in several neuropsychiatric disorders, including substance use disorders. This review discusses the possible mechanisms underlying the therapeutic effects of histamine H3 receptor antagonists on symptoms of methamphetamine abuse.\u0000\u0000\u0000CONCLUSION\u0000Treatment of mice with centrally acting histamine H3 receptor antagonists increases hypothalamic histamine contents and reduces high-dose METH effects, while potentiating low-dose effects, via histamine H1 receptors that bind released histamine. On the basis of experimental evidence, it is hypothesized that histamine H3 receptors may be an effective target for the treatment METH use disorder or other adverse effects of chronic METH use.","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46265851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Belzutifan: A Narrative Drug Review.","authors":"Vysakh Visweswaran, K. Pavithran","doi":"10.2174/2589977514666220401094724","DOIUrl":"https://doi.org/10.2174/2589977514666220401094724","url":null,"abstract":"Von Hippel-Lindau disease is an autosomal dominant disorder characterised by renal cell carcinomas, pancreatic neuroendocrine tumours, central nervous system hemangioblastomas, retinoblastomas, and tumours of the reproductive tract. This disease results from loss of function mutations in the tumour suppressor gene known as the Von Hippel-Lindau gene, located on chromosome 3. Loss of function mutation in the Von Hippel-Lindau gene results in the accumulation of a protein known as a hypoxia-inducible factor, which promotes cellular proliferation and angiogenesis, leading to cancer. Belzutifan inhibits the hypoxia-inducible factor by binding to the Per-ARNT -Sim-B binding pocket on the hypoxia-inducible factor -2α, inhibiting cellular proliferation and angiogenesis. In our thorough literature review, we identified 37 relevant articles. Belzutifan showed clinically meaningful response rates for both Von Hippel-Lindau disease-associated renal cell carcinomas and non-renal cell cancers. The pharmacokinetic profile of belzutifan was much better than its congener molecules due to the optimisation of its dihalide groups from germinal to vicinal. The pharmacodynamic effect of belzutifan was confirmed by its ability to decrease serum erythropoietin, which is a direct result of hypoxia-inducible factor- 2α inhibition. The significant side effects observed were anaemia, hypoxia, fatigue, hypertension, visual impairment and weight gain. Multiple clinical trials are currently underway to determine the role of beluztifan as part of combination regimens in treating Von Hippel-Lindau disease-associated malignancies.","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43119148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK inhibitors as a Barrier to the Destructive Cytokine Storm in COVID-19.","authors":"Ali Saeedi-Boroujeni‬, M. Asadi-Samani","doi":"10.2174/2589977514666220304203816","DOIUrl":"https://doi.org/10.2174/2589977514666220304203816","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47806024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review on structurally diversified synthesized molecules as monoacylglycerol lipase inhibitors and their therapeutic uses.","authors":"Abhishek S. Kashyap, Suresh G. Kumar, R. Dutt","doi":"10.2174/2589977514666220301111457","DOIUrl":"https://doi.org/10.2174/2589977514666220301111457","url":null,"abstract":"Monoacylglycerol is a metabolic key serine hydrolase, engaged in the regulation of signalling network system of endocannabinoids, which is associated with various physiological processes like pain, inflammation, feeding cognition and neurodegenerative diseases like Alzheimer, Parkinson's disease. The monoacylglycerol also found to act as a regulator and the free fatty acid provider in the proliferation of cancer cells, numerous aggressive tumours such as colorectal cancer, neuroblastoma and nasopharyngeal carcinoma. It also played an important role in increasing the concentration of specific lipids derived from free fatty acids like phosphatidic acid, lysophosphatidic acid, sphingosine-1-phosphate and prostaglandin E2. These signalling lipids are associated with cell proliferation, survival, tumour cell migration, contributing to tumour development, maturation and metastases. In the present study here, we are presenting a review on structurally diverse MAGL inhibitors, their development and their evaluation for different pharmacological activities.","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43986704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antipsychotic Medication Risk of Dementia and Death: A Propensity Matched Cohort Study.","authors":"Xiu R Lowe, M. Merchant, Rachel A Whitmer","doi":"10.2174/2589977514666220301102717","DOIUrl":"https://doi.org/10.2174/2589977514666220301102717","url":null,"abstract":"OBJECTIVE\u0000This study aimed to compare the incidence of dementia and all-cause mortality up to 20 years post-treatment in an index non-demented cohort between antipsychotic (AP) medication treatment and non-AP treatment groups.\u0000\u0000\u0000METHOD\u0000All patients in Kaiser Permanente Northern California with a major psychiatric diagnosis between 01/01/1996 and 12/31/2000, age ≥ 50 years, and without dementia diagnosis were included. The study cohort was divided into a \"user group\", patients treated with AP for ≥ 365 days (n = 1,829), and a \"non-user group\", propensity score matched on age, sex, and race (n = 9,145). The association between AP exposure and dementia or mortality during the follow-up period (01/01/2001-12/31/2015) was evaluated using Cox proportional hazard models adjusted for psychiatric diagnosis, comorbidities, and other medications. The user group had a hazard ratio (HR) of 2.2 (CI 1.8-2.7) for dementia and 1.3 (CI 1.2-1.5) for death. The onset of dementia in the user group was significantly higher in patients aged ≤ 65 years (p < 0.001). The user group was sub-grouped into atypical, typical, and both; HR for dementia was 1.7 (CI 1.2-2.4), 2.5 (CI 1.9-3.1), and 1.8 (CI 1.4-2.4), respectively.\u0000\u0000\u0000RESULT\u0000Dementia and mortality were significantly higher in patients concurrently treated with benzodiazepine (HR 1.3; CI 1.2-1.5 and HR 1.4; CI 1.3-1.5) or tricyclic antidepressants (HR 1.2; CI 1.1-1.4 and HR 1.1; CI 1.0-1.2), respectively.\u0000\u0000\u0000CONCLUSION\u0000Our preliminary results reveal an association between AP treatment and increased rates of both dementia and mortality. Future research is needed to substantiate our current findings.","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44965072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of COVID-19 Patients: Scenario so far.","authors":"Manisha Saini,&nbsp;Minakshi Rana,&nbsp;Karun Bhatti,&nbsp;Rina Das,&nbsp;Dinesh Kumar Mehta,&nbsp;Ram Mohan Chidurala","doi":"10.2174/2589977513666210806122901","DOIUrl":"https://doi.org/10.2174/2589977513666210806122901","url":null,"abstract":"<p><p>The novel SARS-CoV-2 is a new disease that has caused severe destruction to human lives across the globe, including infection, mortality and financial crises, for which, scientific researchers have been directed towards the development of treatment and controlling measures against coronavirus. Currently, there has been no approved drug for the treatment of the disease, but several antiviral drugs have shown therapeutic effects from which, remdesivir and favipiravir are two such drugs. These drugs have shown some therapeutic potential in the treatment of COVID-19 by inhibiting viral enzyme RNA-dependent RNA polymerase. The purpose of this systematic review is to provide an overview of the effectiveness of these two drugs based on the clinical trials reported in current published data.</p>","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":"14 1","pages":"11-19"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39289367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Network-based Drug Repurposing: A Critical Review.","authors":"Nagaraj Selvaraj,&nbsp;Akey Krishna Swaroop,&nbsp;Bala Sai Soujith Nidamanuri,&nbsp;Rajesh R Kumar,&nbsp;Jawahar Natarajan,&nbsp;Jubie Selvaraj","doi":"10.2174/2589977514666220214120403","DOIUrl":"https://doi.org/10.2174/2589977514666220214120403","url":null,"abstract":"<p><p>New drug development for a disease is a tedious, time-consuming, complex, and expensive process. Even if it is done, the chances for success of newly developed drugs are still very low. Modern reports state that repurposing the pre-existing drugs will have more efficient functioning than newly developed drugs. This repurposing process will save time, reduce expenses and provide more success rate. The only limitation for this repurposing is getting a desired pharmacological and characteristic parameter of various drugs from vast data about medications, their effects, and target mechanisms. This drawback can be avoided by introducing computational methods of analysis. This includes various network analysis types that use various biological processes and relationships with various drugs to simplify data interpretation. Some of the data sets now available in standard, and simplified forms include gene expression, drug-target interactions, protein networks, electronic health records, clinical trial results, and drug adverse event reports. Integrating various data sets and interpretation methods allows a more efficient and easy way to repurpose an exact drug for the desired target and effect. In this review, we are going to discuss briefly various computational biological network analysis methods like gene regulatory networks, metabolic networks, protein-protein interaction networks, drug-target interaction networks, drugdisease association networks, drug-drug interaction networks, drug-side effects networks, integrated network-based methods, semantic link networks, and isoform-isoform networks. Along with this, we briefly discussed the drug's limitations, prediction methodologies, and data sets utilised in various biological networks for drug repurposing.</p>","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":"14 2","pages":"116-131"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39916614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Pharmacological Targets for the Treatment of Excessive Alcohol use.","authors":"Paolo Mannelli","doi":"10.2174/2589977514666220428125505","DOIUrl":"https://doi.org/10.2174/2589977514666220428125505","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":"160-161"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40571869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Time Depletion Effects on the Volatile Compounds from the Distillation Extracts of Prunella vulgaris and the Dynamics of their Extraction.","authors":"William Chi Keung Mak","doi":"10.2174/2589977514666220429104009","DOIUrl":"https://doi.org/10.2174/2589977514666220429104009","url":null,"abstract":"<p><strong>Background: </strong>Prunella vulgaris (PV) is a low-growing perennial herb, which can be found in different parts of the world as Asia, Europe and North America. It is traditionally used for medicinal treatment in various cultures in India, China, Japan, Korea, Russia, and Eastern Europe for treating different ailments, such as fever, and healing wounds. In our previous article, we showed the anti-tumorous effect of the volatile organic compounds (VOCs) of PV and characterized the steam distillation process in the extraction of VOCs from PV. This has never been done before as we are aware of. To use the VOCs as drugs, there is a question of how much of the VOCs are lost before the prepared drugs reach the patients. Thus, the first aim of the present article is to try to explore the time depletion effect on the VOCs in the PV extracts. Then, the second aim is to extend the work in the previous paper and further understand the dynamics of the distillation process of PV by changing the steam flow rate in the extraction process.</p><p><strong>Methods: </strong>To achieve the first aim to explore the aging effect of how much VOCs are depleted after they are extracted, the VOCs were first extracted by the same method as before, i.e., using steam distillation. Then, tubes of the aqueous solution containing the VOCs were then stored in a 5°C refrigerator. They were then taken out for GC-MS analysis according to a preplanned schedule up to 8 weeks after the VOCs were extracted. The chemical composition of the distillate could then be evaluated. This revealed the changes in the abundance of VOCs with aging. At the same time, the cell viability of SCC154 oral squamous cells treated by these herbal solutions, which were at different aging stages, was evaluated using a tetrazolium-based colorimetric reagent, Cell Counting Kit-8. To achieve the second aim of exploring the dynamics of the steam distillation process, the steam flow rate was adjusted by changing the temperature setting of the hot plate. GC-MS was again used to quantify the chemical constituents of the distillates.</p><p><strong>Results: </strong>By using GC-MS to measure the abundance of volatile compounds at different time points after the distillation process, it was found that the volatile compounds persist for a very long time, or over 8 weeks, which was the longest period of our experiment. The aging of the distillates also did not depreciate much the cell cytotoxicity of the PV distillate on the cancer cells. With respect to the dynamics of the steam distillation process, it was found that, at a low steam flow rate, volatile compounds of lower molecular weight are more efficient to be extracted, while at a high steam flow rate, volatile compounds of higher molecular weight are more efficiently extracted.</p><p><strong>Conclusion: </strong>Our findings demonstrate that the VOC compounds extracted and present in aqueous form do not deplete much for at least 2 months after the extr","PeriodicalId":37008,"journal":{"name":"Current Drug Research Reviews","volume":" ","pages":"148-156"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40401103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}